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Abstract
Background:  Acute infectious diseases are typically accompanied by non-specific symptoms
including fever, malaise, irritability and somnolence that usually resolve on recovery. However, in
some individuals these symptoms persist in what is commonly termed post-infective fatigue. The
objective of this pilot study was to determine the gene expression correlates of post-infective
fatigue following acute Epstein Barr virus (EBV) infection.
Methods: We followed 5 people with acute mononucleosis who developed post-infective fatigue
of more than 6 months duration and 5 HLA-matched control subjects who recovered within 3
months. Subjects had peripheral blood mononuclear cell (PBMC) samples collected at varying time
points including at diagnosis, then every 2 weeks for 3 months, then every 3 months for a year.
Total RNA was extracted from the PBMC samples and hybridized to microarrays spotted with
3,800 oligonucleotides.
Results: Those who developed post-infective fatigue had gene expression profiles indicative of an
altered host response during acute mononucleosis compared to those who recovered uneventfully.
Several genes including ISG20 (interferon stimulated gene), DNAJB2 (DnaJ [Hsp40] homolog and
CD99), CDK8 (cyclin-dependent kinase 8), E2F2 (E2F transcription factor 2), CDK8 (cyclin-
dependent kinase 8), and ACTN2 (actinin, alpha 2), known to be regulated during EBV infection,
were differentially expressed in post-infective fatigue cases. Several of the differentially expressed
genes affect mitochondrial functions including fatty acid metabolism and the cell cycle.
Conclusion: These preliminary data provide insights into alterations in gene transcripts associated
with the varied clinical outcomes from acute infectious mononucleosis.
Background
Acute viral diseases such as infectious mononucleosis typ-
ically present clinically with a cluster of non-specific
symptoms including; fever, an increased need to sleep,
hyperalgesia, anorexia, loss of interest in usual activities,
social interaction, body care, depressed mood, and
impaired concentration [1-3]. This acute sickness behav-
ior response comprises a highly organized and evolved
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disease-fighting strategy mediated by the action of pro-
inflammatory cytokines [4-8]. In general, acute sickness
behavior resolves in parallel with clearance or control of
the infecting agent. However, some individuals exhibit
prolonged illness with fatigue, mood changes and cogni-
tive impairment. Such prolonged illness following infec-
tious mononucleosis has been recognized for at least half
a century [9]. Recent studies of infectious mononucleosis
due to EBV infection demonstrated that fatigue, sore
throat and malaise persisted for up to two months in
approximately 40% of patients and for six or more
months in approximately 10% [10,11]. The risk factors for
and pathophysiology of this post-infective fatigue syn-
drome following EBV infectious mononucleosis have not
been identified. It remains unclear whether post-infective
fatigue reflects chronic effects of persistent EBV (e.g., viral-
mediated) or whether acute EBV infection functions as a
stressor that triggers an altered host response to the virus
leading to ongoing symptoms.
The objective of this pilot study was to assess patients'
gene transcription patterns in the peripheral blood fol-
lowing acute infectious mononucleosis due to EBV and to
determine whether those who recovered uneventfully had
different gene expression profiles than those who devel-
oped post-infective fatigue. To do this, a small cohort of
HLA-matched individuals was followed over one year
after infectious mononucleosis. We found that individu-
als who suffered from post-infective fatigue had a distinct
gene expression profile during acute illness compared to
those whose illness resolved. Evaluation of the gene
expression profile over the course of the year implicated
an altered host response to EBV and mitochondrial dys-
function in those who developed post-infective fatigue.
These data provide insight into alterations in gene tran-
scripts associated with the varied clinical outcomes from
EBV-associated mononucleosis.
Methods
This study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services. All
participants were volunteers who gave written informed
consent.
Subjects were participants in a prospective cohort study
based in the region surrounding the township of Dubbo
in rural New South Wales, Australia. Subjects were
enrolled following presentation to their general practi-
tioner with symptoms suggestive of infectious mononucl-
eosis and laboratory documentation of IgM antibodies
against EBV viral capsid antigen (VCA). These provisional
serological diagnoses were confirmed by repeated testing
of longitudinally collected samples [12]. Most subjects
were assessed at baseline, 2–3 weeks, 4–6 weeks, and 3
months. In those subjects with persistent symptoms, eval-
uation by both a physician and psychiatrist was under-
taken at 6 months to exclude unrelated causes of ongoing
illness. A late follow-up sample (12 months or longer after
baseline) was collected from all subjects. At each visit, self-
report and interview assessments of physical and psycho-
logical health were recorded and a blood sample was col-
lected. A diagnosis of chronic fatigue syndrome (CFS) was
made according to the international diagnostic criteria
[13] in post-infective fatigue cases included in this study.
Those with post-infective fatigue were labeled as cases and
those who recovered as controls. To control for the effect
of genetic influences on immune responses, cases were
matched to controls by HLA -A and -B genotype (with at
least two, and up to four, matched HLA alleles). There
were 5 cases with post-infective fatigue and 5 controls that
recovered promptly. Subjects were also matched by sex
and age. There were 3 females and 2 males in each group
ranging in age from 16 to 49 years. Due to the small
number of subjects, samples were grouped according to
two categorized time periods: early (baseline to 3
months) and late (>6 months following disease onset).
This resulted in 9 early and 8 late samples available from
cases and 6 early and 6 late samples available from con-
trols.
Blood samples
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from blood by density gradient centrifugation (Lym-
phoprep, AXIS-SHIELD, Norway), cryopreserved in RPMI
(Trace, Australia) with 10% DMSO (Sigma, Australia) and
50% autologous plasma, and aliquots stored in the vapor
phase of liquid nitrogen. Total RNA was subsequently
extracted using TRIzol (Invitrogen, Carlsbad, CA) and
RNA integrity and quantity were determined by denatur-
ing gel electrophoresis.
Preparation and hybridization of labeled cDNA
Biotinylated cDNA synthesis from 1 µg of total RNA was
performed as previously described [14]. The cDNA probe
was hybridized to the Atlas™ Human 3.8I oligonucleotide
glass microarrays (CLONTECH Laboratories, Inc., Palo
Alto, CA) using the Ventana Discovery™ system and their
ChipMap™ kit (Ventana Medical Systems, Tucson, AZ).
Hybridization was for 8 hours at 42°C, followed by three
10 minute stringency washes, the final wash in 0.1× SSC
at 42°C. Anti-biotin antibodies conjugated to RLS™ parti-
cles (Invitrogen, Carlsbad, CA) were used for signal detec-
tion as previously described [14]. The slides were archived
and images captured using the GSD-501™ scanner (Invit-
rogen, Carlsbad, CA).
Data analysis
The scanned TIFF images were processed using ArrayVi-
sion™ (Imaging Research Inc., Ontario, Canada) as previ-BMC Infectious Diseases 2006, 6:15 http://www.biomedcentral.com/1471-2334/6/15
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ously described [15]. A median background value was
calculated around each of the 3757 features and sub-
tracted from the mean feature signal to give the net signal
for the respective gene. Flagged features and features with
a signal to noise ratio of <2.5 were excluded. There were
636 genes remaining with a valid signal in 80% or more
of the arrays, that were then log2 transformed and the Z-
score normalized [16].
The Class Comparison analyses were performed using
BRB ArrayTools [17] developed by Dr. Richard Simon and
Amy Peng Lam to determine if gene expression profiles
were different between groups by applying a random var-
iance t-test to the data. Genes were considered statistically
significant with a median false discovery rate of 10%. The
EASE software package [18] was then used to evaluate the
biologic significance of the ontology of genes identified as
differentially expressed by class comparison and to per-
form a statistical analysis of gene categories in the gene list
to find those most over-represented in the arrays [19,20].
To demonstrate the distinct gene clusters, we performed a
two-way hierarchical cluster analysis on the genes identi-
fied by this analytical approach, using the algorithm
described by Eisen et al. [21]. The Reactome curated data-
base [22] was used to map differentially expressed genes
to biological processes in humans [23].
Results
All 10 subjects were followed for at least 12 months fol-
lowing acute EBV infection. To determine if there were dif-
ferences between subjects who developed post-infective
fatigue and those who recovered uneventfully, gene
expression of early samples (baseline to 3 months) from
cases and controls were compared. Twenty-three genes
were differentially expressed during the early time point
between cases and controls (Figure 1). Of these, 8 genes
(35%) were more highly expressed on average in cases
(blue bars) than in controls (orange bars). These over-
expressed genes mapped to cyclin D associated events in
G1 phase of the cell cycle. Four genes were more highly
expressed in controls than in cases and all mapped to
pathways involved in translation initiation and elonga-
There were 23 of 636 genes that were expressed at different levels between cases (blue bars) and controls (orange bars) at the  early time point Figure 1
There were 23 of 636 genes that were expressed at different levels between cases (blue bars) and controls (orange bars) at the 
early time point. The majority of these (15/23) were expressed at higher levels in the cases compared to controls and most 
were involved in cell cycle and metabolism. The four genes known to be involved in translation, were expressed at much lower 
levels in the cases compared to controls.BMC Infectious Diseases 2006, 6:15 http://www.biomedcentral.com/1471-2334/6/15
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tion. Eight genes were expressed only in cases and these
were classified into binding and metabolism ontologies.
Finally, 3 genes have not yet been classified: MARCKS, a
myristoylated alanine-rich protein kinase C substrate;
ENSA, an alpha endosulfine; and, TITF1, thyroid tran-
scription factor 1.
To determine why people with post-infective fatigue
responded differently to acute EBV infection, we next
compared overall gene expression profiles including both
early and late time points in cases and controls. Twenty-
four genes were expressed at similar levels in cases at both
the early and late time points but were significantly differ-
ent from controls (Figure 2). Of these, 22 could be classi-
fied with the molecular function of binding, transporter,
catalytic and signal transducer activity. More specifically,
12 of 24 could be associated with mitochondrial func-
tions including fatty acid oxidation, apoptosis, DNA
repair and mitochondrial membrane.
Cluster analysis of these 24 genes resulted in 2 major
groups (Figure 3). One group was composed predomi-
nately of case samples (11/13; 85%) while the other
group contained 6 case samples and 10 control samples.
There were also 2 major gene groups, one with 17 genes
and the other with the remaining 7 seven genes. In the
larger gene group, 14 of 17 (82%) were up regulated in the
case group and of these, 9 (9/14; 64%) were genes associ-
ated with mitochondrial functions. In the smaller group,
these 7 genes were involved in cell cycle checkpoints and
DNA replication and were down regulated in the case
group.
Discussion
EBV infection in teenage or adult life commonly results in
the symptomatic illness known as infectious mononucle-
osis, which is marked by fever, pharyngitis and lymphad-
enopathy. Infectious mononucleosis typically has a
febrile phase lasting 10 to 14 days. In most infections, a
strong humoral and cellular response is mounted to con-
trol the virus. However, approximately 10% of subjects
with EBV-associated infective mononucleosis remain sick
for at least one year [24,25]. It has recently been shown
that a small proportion of people remain sick with
chronic fatigue syndrome up to 4 years following acute
infectious mononucleosis [26]. This pilot study used gene
expression profiling to determine whether failure to
recover reflected altered gene expression associated with
an altered host response to the acute EBV infection.
The subjects who did not recover from infectious mono-
nucleosis had altered gene expression response during the
early phase of EBV infection compared to those who sub-
sequently recovered uneventfully. Several of the genes that
were differentially expressed in cases were involved in
immune response (ISG20; interferon stimulated gene),
Comparison of genes that were expressed at similar levels during early and late time points for cases (blue bars) but were dif- ferent for controls (orange bars) Figure 2
Comparison of genes that were expressed at similar levels during early and late time points for cases (blue bars) but were dif-
ferent for controls (orange bars). There were 24 of 636 genes that were differentially expressed. Half of these genes have 
known mitochondrial function and are marked with an asterisk.BMC Infectious Diseases 2006, 6:15 http://www.biomedcentral.com/1471-2334/6/15
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apoptosis (DNAJB2; DnaJ (Hsp40) homolog and CD99)
and cell cycle (CDK8; cyclin-dependent kinase 8 and
E2F2; E2F transcription factor 2) functions. It has recently
been shown that EBV exploits these natural antiviral and
cellular defense mechanisms to promote its survival and
persistence in infected B cells [27]. In addition, efficient
replication of the EBV genome is known to involve host
cell cycle-associated proteins [28] including those
encoded by three of the cell cycle genes identified here;
CDK8 (cyclin-dependent kinase 8), E2F2 (E2F transcrip-
tion factor 2) and ACTN2 (actinin, alpha 2). The trans-
membrane and epithelial adhesion protein, COL17A1
(collagen type XVII, alpha 1), that was differentially
expressed, is shed from the cell surface by matrix metallo-
proteases (MMP) [29]. EBV proteins are known to regulate
MMPs potentially altering the viral life cycle and cell
motility [30]. KRTHB3 (basic keratin 3), MUC2 (mucin
2), and PCOLN3 (type III procollagen N-endopeptidase)
all have altered expression in EBV-associated gastric carci-
nomas [31]. Since the majority of these genes are regu-
lated during EBV replication, the fact that these were
differentially expressed in cases potentially implicates a
failure of the host to adequately control viral replication.
To determine why the response to EBV varied between
cases and controls, both early and late time points in the
Cluster analysis of 24 differentially expressed genes of all samples from cases and controls at both early and late time points Figure 3
Cluster analysis of 24 differentially expressed genes of all samples from cases and controls at both early and late time points. 
The samples separated into 2 major groups; one containing most of the case samples and the other containing both cases and 
controls. The genes also grouped into 2 major groups; one that contained most of the mitochondrial function genes that were 
upregulated in cases and the other contained cell cycle checkpoints and DNA replication genes that were down regulated in 
the case group.BMC Infectious Diseases 2006, 6:15 http://www.biomedcentral.com/1471-2334/6/15
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natural history were compared. Of the 24 differentially
expressed genes, half are involved in mitochondrial func-
tions including fatty acid metabolism (CRAT; carnitine
acetyltransferase, APOA2; apolipoprotein A-II), apoptosis
(BTG1; B-cell translocation gene 1, FOLR1; folate receptor
1, CTRL; chymotrypsin-like), and mitochondrial mem-
brane function (COX8A; cytochrome c oxidase subunit
VIII, COX11; cytochrome c oxidase assembly protein,
KCNA10; potassium voltage-gated channel, MGP; matrix
Gla protein; ATP5L; ATP synthase). Several EBV-associ-
ated proteins, such as BRLF1, BHRF1, EBNA and LMP1
have been shown to interfere with fatty acid metabolism,
mitochondrial function and apoptosis pathways [32-35].
Because mitochondria serve several prominent and essen-
tial cellular functions such as energy homeostasis, signal-
ing and apoptosis, it is reasonable to surmise that
alterations in mitochondrial function could affect
immune function. In fact, viral and immune factors have
been evaluated in these same subjects and it was found
that post-infective fatigue was associated with an altered
pattern of humoral immune response against EBV anti-
gens [36]. An increase in the number of apoptotic periph-
eral blood cells has also been demonstrated in patients
with chronic fatigue syndrome [37,38]. Although the
numbers of subjects in this pilot study was small and only
3,800 genes were evaluated, our preliminary results impli-
cate mitochondrial dysfunction as a plausible physiologic
perturbation in post-infective fatigue.
Conclusion
A small proportion of people that develop infectious
mononucleosis following EBV infection remain sick with
chronic fatigue syndrome. Gene expression profiling was
used to determine whether failure to recover reflected
altered gene expression. The subjects who did not recover
from infectious mononucleosis had altered gene expres-
sion response during the early phase of EBV infection
compared to those who subsequently recovered unevent-
fully. There were several differentially expressed genes
identified including gene involved in the immune
response, apoptosis and the cell cycle. A comparison of
gene expression profiles early and late following EBV
infection revealed that those who did not recover had dif-
ferentially expressed genes implicating mitochondrial per-
turbations with fatty acid metabolism, mitochondrial
function and apoptosis pathways.
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